44
Participants
Start Date
February 27, 2023
Primary Completion Date
July 16, 2024
Study Completion Date
July 9, 2025
ZN-c3
ZN-c3 tablet by mouth, in combination with encorafenib
Encorafenib
Encorafenib capsule by mouth, in combination with ZN-c3
Cetuximab
Infusion
Semmelweis University-Department of Internal Medicine and Oncology, Budapest
Peter MacCallum Cancer Centre, Melbourne
Clinexpert Kft. Bugat Pal Korhaz, Gyöngyös
The Queen Elizabeth Hospital, Woodville South
DRK Kliniken Berlin - Köpenick, Berlin
Hospital Universitario Reina Sofia, Córdoba
Istituto Europeo di Oncologia, Milan
ASST Grande Ospedale Metropolitano Niguarda, Milan
Hospital Universitario La Paz, Madrid
Hospital Universitario Puerta de Hierro Majadahonda, Madrid
AOUI Verona, Verona
Fundación Instituto Valenciano de Oncología, Valencia
Institut für Klinisch Onkologische Forschung, Frankfurt am Main
Alliance for Multispecialty Research, LLC, Merriam
IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
University of Texas MD Anderson Cancer Center, Houston
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli
Klinikum der Universität München Großhadern, Munich
Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie, Munich
Hämatologie- Onkologie im Zentrum MVZ GmbH, Augsburg
USC Norris Comprehensive Cancer Center, Los Angeles
Szpital Uniwersytecki w Krakowie, Krakow
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Krakow
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie, Warsaw
Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego, Opole
Hospital Universitari Vall d'Hebron, Barcelona
Parc de Salut Mar - Hospital del Mar, Barcelona
Collaborators (1)
Pfizer
INDUSTRY
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
INDUSTRY